Monday, March 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

Chemical Nerve Agent Pre-Exposure Antidotes

by Global Biodefense Staff
October 5, 2016
Biosecurity Research Programs

Image: HMS (iStock).

Biosecurity Research ProgramsFew antidotes for nerve agents exist, and those that do must be administered soon after an attack. Now a team of scientists report on early-stage development of a potential treatment that soldiers or civilians could take before such agents are unleashed.

One particular antidote, an enzyme called organophosphorus acid anhydrolase (OPAA), has attracted attention recently for its ability to break down nerve agents. But the body’s immune system gets rid of it quickly. Packaging the enzyme in liposome nanocarriers gives the antidote greater staying power, but handling and storing the liposomes is complicated. So the researchers sought to make a potentially simpler carrier.

For a material, the team turned to porous metal-organic frameworks (MOFs), a class of hybrid materials made of metallic ions and organic ligands that are easy to store and handle at room temperature. They used a zirconium-based MOF and loaded it with the antidote.

Testing showed the MOF-encapsulated enzyme was even more effective at breaking down the nerve agent simulant diisopropyl fluorophosphate and the nerve agent soman than the antidote by itself.

The research was supported by the U.S. Defense Threat Reduction Agency, and undertaken by collaborators from Northwestern University, U.S. Army Edgewood Chemical Biological Center, Dalian University of Technology, and King Abdulaziz University.

Read more at ACS Nano: Nanosizing a Metal–Organic Framework Enzyme Carrier for Accelerating Nerve Agent Hydrolysis.

Tags: Chemical Weapons

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC